Glaxo's Corixa deal a shot in the arm for vaccines

LONDON (Reuters) - GlaxoSmithKline Plc's $300 million planned acquisition of Corixa Corp. underlines the British-based group's growing confidence in vaccines as a future driver of growth, industry analysts said on Tuesday.

Continue to Glaxo's Corixa deal a shot in the arm for vaccines on Reuters: Health.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz